But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...
The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.
Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...
The comedian stunned fans with a leggy Valentino mini dress as she shared candid snaps and opened up about her wellness ...
Everyday Health on MSN
New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight
The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much weight loss comes with risks.
In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...
A WOMAN has left people with their jaws on the floor after sharing her epic Mounjaro weight loss journey. Mum Lisa jumped on ...
Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...
Ozempic is finally here — but it doesn’t come cheap. With costs touching ₹11,000 a month and generics still a year away, here ...
Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...
There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...
Novo Nordisk launches Ozempic in India, a type 2 diabetes treatment with weight-loss benefits, starting at ₹2,200 per week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback